Latest NIAID Stories
COSTA MESA, Calif., Jan.
Levels of a protein in the urine of kidney transplant recipients can distinguish those at low risk of developing kidney injury from those at high risk.
A candidate dengue vaccine developed by scientists at the National Institutes of Health (NIH) has been found to be safe and to stimulate a strong immune response in most vaccine recipients.
A drug that targets the antibody immunoglobulin E (IgE), a key player in asthma, nearly eliminated seasonal increases in asthma attacks and decreased asthma symptoms among young people living in inner city environments, a clinical trial sponsored by the National Institutes of Health has found.
MONMOUTH JUNCTION, N.J., July 30 /PRNewswire/ -- Transave Inc.
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.
SRI International, an independent nonprofit research and development organization, today announced the initiation of a tuberculosis (TB) preclinical drug evaluation program in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).
ROCKVILLE, Md., Sept.
A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants at sites in Africa, North America, South America and the Caribbean to test the safety and immune response to the vaccine.